Series A-1 Convertible Preferred Stock [Member]
Class of Stock [Axis]
Series C Convertible Preferred Stock [Member]
Series D Convertible Preferred Stock [Member]
Mab Vax [Member]
Legal Entity [Axis]
Series B Redeemable Convertible Preferred Stock [Member]
Redeemable Convertible Preferred Stock Series B
Equity Components [Axis]
Convertible Preferred Stock Series A-1
Convertible Preferred Stock Series C
Convertible Preferred Stock Series D
Common Stock
Common Stock [Member]
Additional Paid-In Capital
Additional Paid-in Capital [Member]
Accumulated Deficit
Retained Earnings [Member]
Series D Preferred Stock [Member]
MabVax Common Stock Financing [Member]
Research and Development Expense [Member]
Income Statement Location [Axis]
General and Administrative Expense [Member]
Minimum [Member]
Range [Axis]
Maximum [Member]
Stock Option [Member]
Antidilutive Securities [Axis]
Patheon Biologics [Member]
Plan Name [Axis]
Warrant [Member]
Equity Interest Type [Axis]
Stock Option [Member]
Stock Plan [Member]
Award Type [Axis]
Preferred Stock [Member]
Redeemable Convertible Preferred Stock [Member]
Redeemable Mabvax Series A [Member]
Redeemable Mabvax Series B [Member]
Redeemable Mabvax Ther. Series B [Member]
Securities Financing Transactions [Member]
Leasehold Improvements [Member]
Property, Plant and Equipment, Type [Axis]
Equipment [Member]
Office Equipment [Member]
Furniture and Fixtures [Member]
Pre Stock Split [Member]
Post Stock Split [Member]
Telik Acquisition [Member]
Business Acquisition [Axis]
Fair Value, Measurements, Recurring [Member]
Measurement Frequency [Axis]
Investment [Axis]
Fair Value, Inputs, Level 3 [Member]
Fair Value, Hierarchy [Axis]
Two Thousand Eight Stock Incentive Plan [Member]
Two Thousand Fourteen Stock Incentive Plan [Member]
Employee Stock Option [Member]
Board [Member]
Title of Individual [Axis]
Stock Incentive Plans [Member]
Stock Options Outstanding [Member]
Series C Preferred Stock [Member]
Series A- One Preferred Stock [Member]
SeriesC One Redeemable Convertible Preferred Stock [Member]
Series A- Redeemable Convertible Preferred Stock [Member]
Phase Two Study [Member]
Scenario [Axis]
Grant Four [Member]
Type of Arrangement and Non-arrangement Transactions [Axis]
Phase One And Two Study [Member]
Phase One Study [Member]
Grant Two [Member]
Grant One [Member]
Porter Drive [Member]
Parties to Contractual Arrangement [Axis]
Domestic Tax Authority [Member]
Income Tax Authority [Axis]
State and Local Jurisdiction [Member]
Document And Entity Information
Entity Registrant Name
Entity Central Index Key
Document Type
Document Period End Date
Amendment Flag
Current Fiscal Year End Date
Is Entity a Well-known Seasoned Issuer?
Is Entity a Voluntary Filer?
Is Entity's Reporting Status Current?
Entity Filer Category
Trading Symbol
Entity Common Stock, Shares Outstanding
Document Fiscal Period Focus
Document Fiscal Year Focus
Statement [Table]
Statement [Line Items]
Assets
Current assets:
Cash and cash equivalents
Grants receivable
Prepaid expenses - clinical operations
Prepaid expenses
Other current assets
Total current assets
Property and equipment, net
Goodwill
Other long term assets
Total assets
Liabilities, Redeemable Convertible Preferred Stock and Stockholders' Equity
Current liabilities:
Accounts payable
Accrued compensation
Accrued clinical operations and site costs
Related party liabilities
Accrued lease contingency fee
Other accrued expenses
Warrant liability
Total current liabilities
Commitments and contingencies:
Redeemable convertible preferred stock:
Redeemable convertible preferred stock, value
Stockholders' equity:
Convertible preferred stock
Common stock
Additional paid-in capital
Accumulated deficit
Total stockholders' equity
Total liabilities, redeemable convertible preferred stock and stockholders' equity
Redeemable convertible preferred stock, shares authorized
Redeemable convertible preferred stock, shares issued
Redeemable convertible preferred stock, shares outstanding
Redeemable convertible preferred stock, aggregate liquidation value
Preferred stock, shares authorized
Convertible preferred stock, shares issued
Convertible preferred stock, shares outstanding
Convertible preferred stock, liquidation preference
Common stock, par value
Common stock, shares authorized
Common stock, shares issued
Common stock, shares outstanding
Income Statement [Abstract]
Revenues:
Grants
Other
Total revenues
Operating costs and expenses:
Research and development
General and administrative
Total operating costs and expenses
Loss from operations
Interest and other income (expense)
Change in fair value of warrant liability
Net loss
Deemed dividend on Series A-1 preferred stock
Deemed dividend on Series A-1 warrant
Deemed dividend on Series B preferred stock
Accretion of preferred stock dividends
Net loss allocable to common stockholders
Basic and diluted net loss per share
Shares used to calculate basic and diluted net loss per share
Beginning Balance, Shares
Beginning Balance, Amount
Conversion of Series A-1 into common stock on January 10 and February 25, 2015, Shares
Conversion of Series A-1 into common stock on January 10 and February 25, 2015, Amount
Conversion of Series C into common stock on January 10, 2015, Shares
Conversion of Series C into common stock on January 10, 2015, Amount
Conversion of Series B into common stock between March 3 and March 20, 2015, Shares
Conversion of Series B into common stock between March 3 and March 20, 2015, Amount
Accretion of redemption value for Series A-1 from January 1 to March 25, 2015, Shares
Accretion of redemption value for Series A-1 from January 1 to March 25, 2015, Amount
Accretion of redemption value for Series B from January 1 to March 25, 2015, Shares
Accretion of redemption value for Series B from January 1 to March 25, 2015, Amount
Deemed dividend related to exchange of common stock for Series A-1, Series A-1 Warrants and Series B on March 25, 2015, Shares
Deemed dividend related to exchange of common stock for Series A-1, Series A-1 Warrants and Series B on March 25, 2015, Amount
Exchange of Series A-1, and Series A-1 Warrants into common on and Series D on March 25, 2015, Shares
Exchange of Series A-1, and Series A-1 Warrants into common and Series D on March 25, 2015, Amount
Exchange of Series B into common and Series D on March 25, 2015, Shares
Exchange of Series B into common and Series D on March 25, 2015, Amount
Private Placement Issuance of 6,661,000 shares at $0.75 per share, net of issuance costs of $281,023 on March 31, 2015, Shares
Private Placement Issuance of 6,661,000 shares at $0.75 per share, net of issuance costs of $281,023 on March 31, 2015, Amount
Issuance of additional common stock in March 2015 under Common Stock Purchase Agreement in relation to Financing on July 7, 2014, Shares
Issuance of additional common stock in March 2015 under Common Stock Purchase Agreement in relation to Financing on July 7, 2014, Amount
Elimination of warrant liability in exchange transaction
Stock-based compensation
Net loss
Ending Balance, Shares
Ending Balance, Amount
Condensed Consolidated Statements Of Cash Flows
Operating activities
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization
Change in fair value of warrants
Increase (decrease) in operating assets and liabilities:
Grants receivable
Other receivables
Prepaid expenses - clinical operations
Prepaid expenses and other
Accounts payable
Accrued clinical operations and site costs
Accrued compensation
Related party liabilities
Other accrued expenses
Net cash used in operating activities
Investing activities
Purchases of property and equipment
Proceeds from acquisition of Telik, Inc.
Net cash used in investing activities
Financing activities
Issuances of preferred stock, net of issuance costs
Proceeds from exercise of warrants
Issuances of common stock, net of issuance costs
Net cash provided by financing activities
Net change in cash and cash equivalents
Cash and cash equivalents at beginning of year
Cash and cash equivalents at end of year
Supplemental disclosures of cash flow information:
Cash paid during the period for income taxes
Supplemental disclosures of non-cash investing and financing information:
Deemed dividend on beneficial conversion feature for preferred stock
Accretion of redemption value for Series A-1 and B preferred stock
Issuance of common stock for accounts payable
Goodwill on acquisition of Telik, Inc.
Conversion of Series A-1 redeemable preferred stock into common stock
Conversion of Series C preferred stock to common stock
Conversion of Series B preferred stock to common stock
Exchange of Series A-1 preferred stock and warrants into common stock and Series D preferred stock
Exchange of Series B preferred stock and warrants into common stock and Series D preferred stock
Acquisition of MabVax Therapeutics Holdings in relation to the merger
Warrants exercised to purchase common stock on a cashless basis to purchase 488,659 shares of common stock. See Note 7.
Notes to Financial Statements
Basis of Presentation
Accounting Policies [Abstract]
Summary of Significant Accounting Policies
Accounting Changes and Error Corrections [Abstract]
Recent Accounting Pronouncements
Liquidity and Going Concern
Cash and Cash Equivalents [Abstract]
Cash and Cash Equivalents
Fair value of financial instruments
Property, Plant and Equipment [Abstract]
Property and Equipment, Net
Equity [Abstract]
Reverse Stock Split, Name Change and Increase in Authorized Shares
Business Combinations [Abstract]
Merger with MabVax Therapeutics, Inc.
Convertible Preferred Stock, Common Stock and Warrants
Stock-based Activity
Net Loss per Share
Contracts and Agreements
Commitments and contingencies
Income Tax Disclosure [Abstract]
Income taxes
Subsequent Events
Basis Of Presentation Policies
Nature of operations and basis of presentation
Recent Accounting Pronouncements
Basis of Presentation
Use of Estimates
Cash and Cash Equivalents
Fair Value of Financial Instruments
Grants Receivable
Property and Equipment
Impairment of Long-lived Assets
Impairment of Goodwill
Revenue Recognition
Research and Development Costs
Stock-based Compensation
Income Taxes
Fair Value Measurements
Schedule of Property and Equipment
Schedule of Estimated Purchase Price of Acquisition
Schedule of Warrant Liability Valuation Assumptions
Schedule of Financial Instruments Measured at Fair Value on a Recurring Basis
Schedule of Changes in the Value of the Warrant Liability
Stock-based Activity Tables
Stock-based Compensation
Stock-based Award Activity
Valuation Assumptions Used to Determine Stock-based Expense
Common stock reserved for future issuance
Net Loss Per Share Tables
Potentially dilutive securities
Commitments and Contingencies Disclosure [Abstract]
Minimum Future Annual Operating Lease Obligations
Components of Provision for Income Taxes
Significant Components of Deferred Tax Assets
Computation of Provision for Income Taxes Differs from Expected Tax Expense
Summary Of Significant Accounting Policies [Table]
Summary Of Significant Accounting Policies [Line Items]
Reverse stock split on common stock ratio
Reverse stock split, description
Number of operating segments
Net cash used for operating activities
Net cash provided by investing activities
Financing to be raised through the sale and issuance shares
Issuance costs
Estimated useful lives
Impairment losses of long-lived assets
Impairment of goodwill
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Net cash used for operating activities
Net cash provided by investing activities
Net cash provided by financing activities
Accumulated deficit
Property, Plant and Equipment [Table]
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross
Less accumulated depreciation and amortization
Property, plant and equipment, net
Depreciation expense
Temporary Equity, by Class of Stock [Table]
Temporary Equity [Line Items]
Number of outstanding shares
Schedule of Business Acquisitions, by Acquisition [Table]
Business Acquisition [Line Items]
Purchase Consideration
Telik Assets:
Cash and Cash Equivalents
Accounts Receivable
Prepaids and Other Current Assets
Telik Assets
Telik Liabilities:
Accrued Compensation
Accrued Liabilities
Accrued Contingent Termination Fee
Warrant Liability
Telik Liabilities
Merger agreement, entry date
Merger agreement, effective date
Common stock exchange ratio
Ownership percentage of MabVax equity holders
Ownership percentage of former Telik equity holders
Purchase price consideration
Business acquisition, common stock closing price
Business acquisition, common stock shares
Cash balance exceeding FDIC limits
Adjustment in redemption value
Preferred stock, shares issued
Preferred stock, shares outstanding
Common stock issuable upon conversion of preferred
Shares issued
Unit sale price
Warrants issued
Warrant price
Proceeds from issuance of preferred stock and warrants
Shares issued, issuance costs
Financing raised through the sale and issuance of shares of common stock
Gain on warrant liability
Preferred stock converted into common shares
Common stock issued upon conversion of preferred
Deemed dividends
Fair Value Disclosures [Abstract]
Risk-free interest rate
Dividend yield
Expected volatility
Expected life of options, in years
Market price for common stock
Warrant exercise price, adjusted
Fair Value Measurements, Recurring and Nonrecurring [Table]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Financial liabilities
Fair value - beginning of year
Fair value on acquisition
Change in fair value
Fair value - end of year
Related Party Transactions [Abstract]
Consulting fee
Shares of common stock in exchange for cancellation of related party liabilities
Severance and benefits costs
Accrued severance and benefits costs
Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Total stock-based compensation expense
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Weighted Average Exercise Price
Weighted-Average Exercise Price, Outstanding at beginning of period
Weighted-Average Exercise Price, Granted
Weighted-Average Exercise Price, Exercised
Weighted-Average Exercise Price, Forfeited/cancelled/expired
Weighted-Average Exercise Price, Outstanding and expected to vest at end of period
Weighted-Average Exercise Price, Vested and exercisable at March 31, 2015
Shares Issuable Under Options
Options Outstanding, Outstanding at beginning of period
Options Outstanding, Granted
Options Outstanding, Exercised
Options Outstanding, Forfeited/cancelled/expired
Options Outstanding, Outstanding and expected to vest at end of period
Options Outstanding, Vested and exercisable at March 31, 2015
Common stock reserved for future issuance
Schedule Of Nonvested Restricted Stock Activity [Line Items]
Total share-based compensation expense
Weighted-Average Exercise Price, Vested and exercisable at December 31, 2014
Options Outstanding, Vested and exercisable at December 31, 2014
Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Risk-free interest rate
Dividend yield
Expected volatility
Expected life of options, in years
Weighted-average grant date fair value
Schedule of Deferred Compensation Arrangement with Individual, Share-based Payments [Table]
Deferred Compensation Arrangement with Individual, Share-based Payments [Line Items]
Authorized for future grant or issuance under the Stock Plan
Number of shares reserved for issuance under Plan
Unrecognized stock-based compensation expense, options
Unrecognized stock-based compensation expense, recognition period
Weighted average remaining Contractual term, stock options outstanding
Number of shares authorized under the Stock Plan
Stock Options granted
Stock issued during period new issue of shares
Issuance of shares contingent upon forfeiture, expiration or cancellation
Maximum term of options granted under Stock Plan
Vesting percentage
Employee option grants vest percentage on first anniversary
Description of share based award
Forfeiture rate
Stock options vested, number of shares
Stock option vesting period
Tax benefits for tax deductions related to stock-based compensation
Stock options exercised
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Shares excluded from diluted net loss per common share calculations
Expense
Revenue for NCI PET
Agreements [Table]
Agreements [Line Items]
Contract awarded
Revenue from grants
Extension period on project
2015
Total
Schedule of Operating Leased Assets [Table]
Operating Leased Assets [Line Items]
Contingent lease termination fee
Additional financing amount
Lease amendment date
Lease expiration date
Refundable security deposit
Rent expense
Number of employees separated
Severance and benefits costs to be paid
Current:
Federal
State
Current Income Tax Expense (Benefit)
Deferred:
Federal
State
Deferred Income Tax Expense (Benefit)
Income tax expense
Deferred tax assets:
Net operating loss carryforwards
Tax credits
Accrued expenses and other
Total deferred tax assets
Less valuation allowance
Net deferred tax assets
Tax benefit computed at 34%
State tax provision, net of federal tax benefit
Change in valuation allowance
Other
Income Taxes [Table]
Income Taxes [Line Items]
Allowances against the net deferred tax assets
Research and development credit carryforwards
Other deferred tax asset
Total deferred tax assets
Operating loss carryforwards
U.S federal and state net operating losses expiration
Research credit carryforward expiration period
Ownership change description
Tax benefit measured and recognized at the largest amount
Series A1 Convertible Preferred Stock [Member]
Series C Convertible Preferred Stock [Member]
custom:SeriesDConvertiblePreferredStockMember
Accrued contingent lease termination fee.
Fair value of PIPE warrant as of reporting date. These warrants become exercisable six months from May 13, 2014, expire five year from May 13, 2014 with an initial exercise price of $3.33 per share. On the 60th day following the earlier of (i) the date all of the shares underlying the PIPE warrants become registered pursuant to an effective registration statement and (ii) six months following the PIPE closing date, or in each case, the reset date, the exercise price will be reset to equal the lower of (i) the current exercise price and (ii) 90% of the average of the 10 lowest weighted average prices of common stock during the 20 trading days immediately preceding the reset date.
MabVax [Member]
Series B Redeemable Convertible Preferred Stock [Member]
Change in fair value of warrants.
Accretion of redemption value for Series A-1 and B preferred stock.
Conversion of Series C preferred stock to common stock.
Conversion of Series B preferred stock to common stock.
Exchange of Series A-1 preferred stock and warrants into common stock and Series D preferred stock.
Exchange of Series B preferred stock and warrants into common stock and Series D preferred stock.
custom:ConvertiblePreferredStockSeriesAOneMember
custom:ConvertiblePreferredStockSeriesCMember
custom:ConvertiblePreferredStockSeriesDMember
Conversion of Series A-1 into Common stock on January 10 and February 25, 2015, Shares.
Conversion of Series A-1 into Common stock on January 10 and February 25, 2015, Amount.
Conversion of Series C into Common stock on January 10, 2015, Shares.
Conversion of Series C into Common stock on January 10, 2015, Amount.
Conversion of Series B into Common stock between March 3 and March 20, 2015, Shares.
Conversion of Series B into Common stock between March 3 and March 20, 2015, Amount.
Accretion of redemption value for Series A-1 from January 1 to March 25, 2015, Shares.
Accretion of redemption value for Series A-1 from January 1 to March 25, 2015, Amount.
Accretion of redemption value for Series B from January 1 to March 25, 2015, Shares.
Accretion of redemption value for Series B from January 1 to March 25, 2015, Amount.
Exchange of Series A-1 into Common and Series D on March 25, 2015, Shares.
Exchange of Series A-1 into Common and Series D on March 25, 2015, Amount.
Exchange of Series B into Common and Series D on March 25, 2015, Shares.
Exchange of Series B into Common and Series D on March 25, 2015, Amount.
Private Placement Issuance of 6,661,000 shares at $0.75 per share, net of issuance costs of $281,023 on March 31, 2015, Shares.
Private Placement Issuance of 6,661,000 shares at $0.75 per share, net of issuance costs of $281,023 on March 31, 2015, Amount.
Issuance of additional Common stock in March 2015 under Common Stock Purchase Agreement in relation to Financing on July 7, 2014, Shares.
Issuance of additional Common stock in March 2015 under Common Stock Purchase Agreement in relation to Financing on July 7, 2014, Amount.
Elimation of warrant liability.
custom:LiquidityAndGoingConcernTextBlock
Prepaid Clinical Expenses Current
Warrants to purchase common stock value
Regulatory Assets [Abstract]
Summary Of Significant Accounting Policies [Table]
Summary Of Significant Accounting Policies [Line Items]
Securities financing transactions.
Pre Stock Split [Member]
Post Stock Split [Member]
Common Stock Exchange Ratio
Telik Acquisition [Member]
Business combination recognized identifiable assets acquired and liabilities assumed accrued compensation.
Business combination recognized identifiable assets acquired and liabilities assumed warrant liability.
Series A- Redeemable Convertible Preferred Stock [Member]
Series A- One Preferred Stock [Member]
Issuance Of Common Stock To Related Parties For Consulting Services Shares
Two Thousand Eight Stock Incentive Plan [Member]
Two Thousand Fourteen Stock Incentive Plan [Member]
Board [Member]
Share based compensation arrangement by share based payment award contingent upon forfeiture expiration or cancellation.
Forfeiture Rate
Schedule Of Nonvested Restricted Stock Activity [Line Items]
Stock Incentive Plans [Member]
Stock Options Outstanding [Member]
SeriesC One Redeemable Convertible Preferred Stock [Member]
Agreements [Table]
Agreements [Line Items]
Phase Two Study [Member]
Grant Four [Member]
Phase One And Two Study [Member]
Phase One Study [Member]
Grant Two [Member]
Grant One [Member]
Agreement extension period.
Porter Drive [Member]
Amount of additional financing to trigger additional termination fee.
Lease amendment effective date.
Income Taxes [Table]
Income Taxes [Line Items]
Operating Loss Carryforwards Expiration Period One
Deferred tax assets tax credit carry-forward expiration period.
Tax benefit likelihood of being realized upon settlement.
Equity Option [Member]
Assets, Current
Assets [Default Label]
Liabilities, Current
Stockholders' Equity Attributable to Parent
Liabilities and Equity
Revenues
Operating Expenses
Operating Income (Loss)
Preferred Stock Dividends, Income Statement Impact
Temporary Equity, Accretion to Redemption Value, Adjustment
Net Income (Loss) Available to Common Stockholders, Basic
Shares, Issued
Increase (Decrease) in Receivables
Increase (Decrease) in Other Receivables
Increase (Decrease) in Prepaid Expense
Increase (Decrease) in Prepaid Expenses, Other
Increase (Decrease) in Accounts Payable
Increase (Decrease) in Accrued Liabilities
Increase (Decrease) in Accrued Salaries
Increase (Decrease) in Accounts Payable, Related Parties
Increase (Decrease) in Other Accrued Liabilities
Net Cash Provided by (Used in) Operating Activities, Continuing Operations
Payments to Acquire Property, Plant, and Equipment
Net Cash Provided by (Used in) Investing Activities, Continuing Operations
Cash and Cash Equivalents, Period Increase (Decrease)
New Accounting Pronouncements, Policy [Policy Text Block]
Cash and Cash Equivalents, Policy [Policy Text Block]
Schedule of Compensation Cost for Share-based Payment Arrangements, Allocation of Share-based Compensation Costs by Plan [Table Text Block]
Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets
Fair Value, Measurement with Unobservable Inputs Reconciliations, Recurring Basis, Liability Value
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number
Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term
Current Income Tax Expense (Benefit)
Deferred Federal Income Tax Expense (Benefit)
Deferred State and Local Income Tax Expense (Benefit)
Deferred Income Tax Expense (Benefit)
Income Tax Expense (Benefit)
Deferred Tax Assets, Net of Valuation Allowance
Effective Income Tax Rate Reconciliation, Other Reconciling Items, Amount
RegulatoryAssetsAbstract